Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study
RMD Open · 2026-07 · 12 (3) · e006830
DOI: 10.1136/rmdopen-2026-006830 ↗Kurz gefasst
Fachartikel in der Zeitschrift RMD Open, online erschienen am 30.07.2026. Verfasst von Vincenzo Venerito und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy vincenzo.…. Hauptthemen laut MEDLINE: Tirzepatide, Obesity, Arthritis, Psoriatic, Biological Products. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate 6-month clinical outcomes in obese patients with psoriatic arthritis (PsA) who initiated tirzepatide concurrently with biologic therapy compared with those starting biologics alone.
Methods
Propensity score-matched comparative study at tertiary care rheumatology centres. Patients with PsA with body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity initiating tirzepatide (2.5 mg/week, uptitrated to 5 mg/week after 1 month) with biologic therapy were prospectively enrolled from January 2025. Controls initiating biologics alone (2021–2025) were matched 1:2 on BMI, disease duration, Disease Activity Index for Psoriatic Arthritis (DAPSA) and Psoriasis Area and Severity Index (PASI). Outcomes at 6 months included minimal disease activity, DAPSA low disease activity (≤14), PsA Impact of Disease-12 (PsAID-12) Patient Acceptable Symptom State (PASS ≤4), Health Assessment Questionnaire (HAQ ≤0.5), PASI ≤1, Visual Analogue Scale pain and C reactive protein (CRP). Continuous outcomes were additionally analysed with ANCOVA adjusted for baseline and a mixed (time × group) model.
Results
Thirty-one patients completed 6 months and were matched to 62 controls. Baseline characteristics were well balanced. The tirzepatide group showed greater BMI reduction (−2.9±2.0 vs +0.4±1.2 kg/m², p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy vincenzo.venerito@gmail.com.
- Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy.
- Libera Università Mediterranea Jean Monnet, Bari, Italy.
Zitieren
APA
Venerito, V., Lopalco, G., Colaprico, C., Catamerò, D., Cacciapaglia, F., & Iannone, F. (2026). Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study. RMD Open, 12(3), e006830. https://doi.org/10.1136/rmdopen-2026-006830
Vancouver
Venerito V, Lopalco G, Colaprico C, Catamerò D, Cacciapaglia F, Iannone F. Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study. RMD Open. 2026;12(3):e006830. doi:10.1136/rmdopen-2026-006830
BibTeX
@article{Venerito2026,
author = {Venerito, Vincenzo and Lopalco, Giuseppe and Colaprico, Cristiana and Catamerò, Daniele and Cacciapaglia, Fabio and Iannone, Florenzo},
title = {Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study},
journal = {RMD Open},
year = {2026},
volume = {12},
number = {3},
pages = {e006830},
doi = {10.1136/rmdopen-2026-006830}
}
EUVIMED